Table 1.
Means (Standard Deviations) for Each Physical Health Outcome by At Least One- and Two-Level Reductions at Each Assessment Timepoint
| Outcome | No change or increase Mean (SD) | At least 1-level reduction Mean (SD) | 1-level reduction, no change, or increase Mean (SD) | At least 2-level reduction Mean (SD) |
|---|---|---|---|---|
| SBP (mm/Hg) | ||||
| Week 16 | 137.9 (17.6) | 129.8 (16.6) | 134.2 (17.1) | 129.5 (16.6) |
| Week 26 | 138.6 (17.5) | 130.3 (17.9) | 135.5 (19.2) | 129.9 (17.3) |
| Week 52 | 136.7 (16.9) | 130.6 (17.2) | 134.4 (17.7) | 130.3 (16.9) |
| AST (IU/L) | ||||
| Week 16 | 41.0 (35.7) | 28.2 (16.0) | 36.2 (29.1) | 27.7 (14.7) |
| Week 26 | 38.5 (34.9) | 29.6 (26.8) | 35.4 (29.8) | 29.2 (27.7) |
| Week 52 | 40.3 (37.5) | 31.2 (29.9) | 37.7 (33.8) | 30.5 (30.3) |
| ALT (IU/L) | ||||
| Week 16 | 40.8 (32.6) | 30.8 (23.5) | 38.0 (28.9) | 30.1 (23.1) |
| Week 26 | 40.8 (38.9) | 30.9 (22.2) | 36.7 (31.5) | 30.8 (22.9) |
| Week 52 | 41.3 (29.7) | 33.9 (33.9) | 40.4 (30.8) | 32.8 (34.3) |
| GGT (IU/L) | ||||
| Week 16 | 145.1 (467.1) | 43.5 (61.9) | 87.3 (303.6) | 42.9 (63.3) |
| Week 26 | 86.6 (223.3) | 47.2 (73.2) | 73.8 (172.6) | 44.9 (72.8) |
| Week 52 | 108.6 (245.4) | 53.4 (79.4) | 29.5 (197.3) | 51.2 (75.1) |
Note. All numbers are observed (percentages are based on valid number of cases) with no imputation for missing data. Biomarker assessments were conducted at the end of treatment (week 16 after baseline) and at two assessments after treatment: 10 weeks post-treatment (post-baseline week 26), and 36 weeks post-treatment (post-baseline week 52). SBP=Systolic blood pressure; AST=aspartate aminotransferase; ALT=alanine aminotransferase; GGT=γ-glutamyltransferase; IU/L=International Units per Liter.